Biogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical needs, the company faces challenges amidst concerns over its earnings...
A combination of a Shark harmonic pattern and a Gartley has emerged at the pattern completion zone. There is also bullish divergence on the RSI at the comfirmation double bottom. NASDAQ:BIIB has been oscillating between around $190-$440 since 2013 and seems to be at a good bargain price of $218 currently which is on the lower side.
NASDAQ:BIIB is forming a Bearish Gartley pattern after attempting a breakout. Gartly patterns are one of the most common harmonic patterns.
Typically the stop-loss on these patterns can be set at the first leg of the pattern around the $270 mark.
BIIB's at a support level, but it's also been gapping up significantly every 2-6 quarters for the past few years. Its last gap was exactly a year ago, so it's overdue for a gap up. It's also within a month of earnings, so management is likely keen on pushing for newsworthy developments. I'll be rolling far OTM calls every week until earnings given the upside for...
Biogen has a monster trade brewing here, can't afford to miss this trade. I've been trading it actively since they received FDA approval for their Alzheimer's drug a while back.
The current setup looks very strong and implies a massive uptrend can start from right here.
Best of luck!
Ivan Labrie.
Biogen Inc. (BIIB) currently testing channel support, able to absorb weekly selling pressures.
From here, (BIIB) can recover and turn higher to channel resistance, eliciting gains of 20-25% over the following 2 - 3 months.
A settlement above this week’s high would accelerate this upward momentum.
Inversely, closing below this channel support would indicate...
Biogen (BIIB) earnings are on Wednesday, July 19th, 2023, at 7:15am. Biogen (BIIB) reported Q1 March 2023 earnings of 3.40 per share on revenue of 2.5 billion. The consensus earnings estimate was 3.25 per share on revenue of 2.4 billion. The company said it continues to expect 2023 earnings of 15.00 to 16.00 per share. The current consensus earnings estimate is...
BIIB shares might the consolidation channel and prepare a move higher.
The reason would be that the market discounts the potential sales CAGR for Alzheimer's drugs, reimbursements being an issue.
If the problem gets solved, BIIB gets a clear path towards higher valuation.
On the chart, we can see a head and shoulders forming.
It's currently at the neckline, from which a breakout will activate our short position.
Both MACD and RSI are showing bearish crossings.
More info is shown on the chart.
Good luck!
According to MarketWatch, The FDA approved the
Alzheimer's drug Legembi from
Eisai and Biogen
A quick look at the daily charts for $BIIB shows that it's already trading on or above major moving averages (ie. 9,21,50 SMA's). Also, seeing as this is a nice, green day for the SPY and BIIB has been beaten down recently, it's a nice long option for medium term traders...
In downtrend, bounced back to Supply zone
Current Monthly chart price range 73 - 217
Earning 7/26/2022 Estimate 4.09
Short 200
Stop 220
Target 140
Risk management is much more important than a good entry point.
I am not a PRO trader.
In my trading plan, the Max Risk of each short term trade should be less than 1% of an account.
Order SELL BIIB NASDAQ.NMS Stop 278.12 LMT 278.12 will be automatically canceled at 20230401 01:00:00 EST
BIIB daily bearish hammer end of wave 5 expect correction at the very least
The PEAD projected a Neutral outlook for $BIIB after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 75%.
